

・研究成果の刊行に関する一覧表

書籍 : なし

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H, Ochiai A.	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric Cancer.	18(2)	227-38	2015
Doi T, Onozawa Y, Fuse N, Yoshino T, Yamazaki K, Watanabe J, Akimov M, Robson M, Bokku N, Ohtsu A.	Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.	Cancer Chemotherapy Pharmacol.	74(3)	629-36	2014
Yano T, Ono H, Doi T, Hasegawa H, Honda M, Oono Y, Ikematsu H, Tanaka M, Kakushima N, Kaneko K, Sato A, Ohtsu A.	Endoscopic submucosal dissection using a new scissors-type electrosurgical knife: a first-in-human feasibility study.	Endoscopy.	46(9)	754-7	2014
Doi T, Ma Y, Dhanraj, Montabaktuni A, Nippgen C, Nippgen J, Ohtsu A.	Phase I study of olaratumab in Japanese patients with advanced solid tumors.	Cancer Sci.	105(7)	862-9	2014
Ando Y, Inada-Inoue M, Mitsunuma A, Yoshino T, Ohtsu A, Suganaga N, Sato M, Kakizume T, Robson M, Quadt C, Doi T.	Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.	Cancer Sci	105(3)	347-53	2014
Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y.	Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.	Invest New Drugs.	32(2)	261-70,	2014

Takahari D, Bokku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, Yamazaki K, Koizumi W, Fukase K, Yamaguchi K, Goto M, Nishina T, Tamura T, Tsuji A, Ohtsu A.	Determination of Prognostic Factors in Japanese Patients With Advanced Gastric Cancer Using the Data From a Randomized Controlled Trial, Japan Clinical Oncology Group 9912.	Oncologist	19(4)	358-66	2014
Takashima A, Bokku N, Kato K, Nakamura K, Mizusawa J, Fukuda H, Shira K, Shimada Y, Ohtsu A	Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912	Gastric Cancer	17(3)	522-8	2014
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwano Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I.	Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.	Ann Oncol	26(1)	141-8	2015
Yasui H, Muro K, Shimada Y, Tsuji A, Samehima S, Baba H, Satoh T, Deno T, Ina K, Nishina T, Yamaguchi K, Esaki T, Tokunaga S, Kuwano H, Bokku N, Komatsu Y, Watanabe M, Hyodo I, Morita S, Sugihara K.	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FOLFIRIS study.	J Cancer Res Clin Oncol	141(1)	153-60	2015

Funakoshi T, Yasui H, Bokun N, Fukutomi A, Yamazaki K, Machida N, Toridaka A, Tsushima T, Yokota T, Onozawa Y, Kenmotsu H, Endo M	Clinicopathological Features and Outcomes of Gastric Cancer Patients with Pulmonary Lymphangitis Carcinomatosa.	Jpn J Clin Oncol	44(9)	792-8	2014
Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, Kondizumi W, Tohyama Y, Hara T, Miyata Y.	Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.	Cancer Sci.	105(7)	812-7	2014
Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, Yoshino T, Asano H, Ochiai A, Komatsu Y, Sakamoto N, Ohtsu A	Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.	Jpn J Clin Oncol	45(1)	43-8	2015
Abe A, Kuwata T, Yamauchi C, Higuchi Y, Ochiai A	High Mobility Group Box1(HMGB1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts.	Pathol Int	64(6)	267-75	2014
Mukai, H; Takahashi, S; Nozawa, M; Onozawa, Y; Miyazaki, J; Ohno, K; Suzuki, K.	Phase I dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer.	Cancer Chemother Pharmacol.	73(4)	703-10	2014
Nishio M, Horike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudoh K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.	Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.	Invest New Drugs.	Published on line		2015

Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Muro K, Akagi K	Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.	World J Gastroenterol	21 (4)	1275-83	2015
Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Takahashi A, Kakuta M, Nishimura Y, Yamaguchi K	Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.	J Surg Oncol	110(8)	982-8	2014
Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Yamamoto G, Nishimura Y, Yamaguchi K	Inverse effect of mucinous component on survival in stage III colorectal cancer.	J Surg Oncol	110(7)	851-7	2014
土原一哉	国内における臨床シークエンスの展開	医学の歩み	249	1133-1138	2014
土原一哉	生検材料の臨床シークエンスがもたらす新しいがん診療	病理と臨床	32	888-894	2014
Fujiwara T, Takahashi RU, Kosaka N, Nezu Y, Kawai A, Ozaki T, Ochiya T.	RPN2 gene confers osteosarcoma cell malignant phenotypes and determines clinical prognosis	Mol Ther Nucleic Acids	3	e189	2014
Takahashi RU, Ochiya T.	RPN2: a promising therapeutic target for breast cancer?	J Stem Cell Res, Rev & Rep	1	2	2014
Tominaga N, Fujiwara K, Kosaka N, Honma K, Nakagama H, Ochiya T.	RPN2-mediated glycosylation of tetraspanin CD63 regulates breast cancer cell malignancy.	Mol Cancer	13	134	2014